Rallybio reports data from its ongoing Phase 1b study of RLYB211 showing significant benefit over placebo. RLYB211, a plasma-derived polyclonal anti-HPA-1a antibody, is being evaluated for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).
The new data show that administration of RLYB211 accelerated the elimination of HPA-1ab-positive platelets through 7 days following administration compared with placebo. The study simulated a real-world treatment approach to preventing FNAIT.
“This result reinforces our preventative approach to FNAIT for mothers and babies at-risk for this potentially life-threatening-disease,” said Martin Mackay, CEO of Rallybio.